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APROTININ VERSUS 
DESMOPRESSIN FOR 
PATIENTS UNDERGOING 
OPERATIONS WITH 
CARDIOPULMONARY 
BYPASS 
A double-blind placebo- 
controlled study 
Background. Aprotinin reduces blood loss in operations done with cardio- 
pulmonary bypass, whereas the use of desmopressin remains controversial. 
We compared aprotinin, desmopressin, and placebo in a double-blind, 
randomized trial to evaluate bleeding and transfusion requirements. 
Methods and results. One hundred forty-nine patients (48 received aprotinin, 
50 desmopressin, 51 placebo) were included. Blood loss and transfusion 
requirements were recorded and levels of Factor VIII coagulant activity, 
von Willebrand's factor, thrombin-antithrombin complexes, and D-dimer 
were measured. Overall blood loss was 195 -+ 146 ml/m 2 in the aprotinin 
group, 400 -+ !92 ml/m 2 in the desmopressin group, and 489 _+ 361 ml/m 2 
in the placebo group (95% confidence intervals: difference between desmo- 
pressin and aprotinin 98 to 312 ml/m 2, p < 0.001; difference between 
placebo and aprotinin 190 to 398 ml/m 2, p < 0.001). Twenty-six percent of 
patients treated with aprotinin, 66% of those treated with desmopressin, 
and 56% of those treated with placebo were given transfusion (95% 
confidence intervals: difference between aprotinin versus placebo plus 
desmopressin 51% to 71%, p < 0.001). Fibrinolytic activation throughout 
cardiopulmonary bypass was markedly higher with placebo or desmopres- 
sin administration. D-dimer level correlated with overall blood loss in 
patients receiving desmopressin or placebo, but not in those receiving 
aprotinin. Conclusion. Aprotinin administration reduces blood loss and 
transfusion requirements in cardiopulmonary bypass. This benefit may be 
explained by a lower activation of fibrinolysis. (J THORAC CARBIOVASC SURG 
1995;110:1107-17) 
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H emorrhage is a common and important problem in patients undergoing operations done with 
cardiopulmonary b pass (CPB) and carries a major 
risk of early and late complications. Continued 
concern about the risks of blood transfusions and 
the problems of occasional shortages of donor blood 
and increasing costs have stimulated interest in 
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blood conservation. Risks include transfusion reac- 
tions, blood component alloimmunization, transmis- 
sion of blood-borne viruses (human immunodefi- 
ciency virus, human T-cell leukemia virus type I, 
cytomegalovirus, hepatitis viruses), 1-2 and transfu- 
sion-associated graft-versus-host disease. 3 
The cause of increased nonsurgical bleeding after 
a period of CPB is difficult to define because of 
alterations in several factors that control normal 
hemostasis. Hemodilution reduces clotting factors 
and platelets. In addition, platelet function is im- 
paired and a defect in the formation of the platelet 
plug is thought to be one of the most important 
causes of bleeding. There is a prolongation of 
bleeding time during and after CPB. Blood contact 
with foreign surfaces causes a marked activation of 
coagulation and secondary activation of the fibrino- 
lytic system. Excessive bleeding may also arise as a 
result of other causes such as the prior use of 
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Table I. Demographic data and characteristics of
the three groups 
Characteristic Aprotinin Desmopressin Placebo 
No. of patients 48 50 51 
Age (yr) 57 _+ 10 58 -+ 12 54 _+ 12 
Sex 
Male 31 33 31 
Female 17 17 20 
Previous medica- 
tion (No. of 
patients) 
Anticoagulants 7 12 11 
Antiaggregants 7 7 5 
Operative proce- 
dure 
CABG 19 19 21 
Valve replace- 22 24 19 
ment 
CABG and 1 0 3 
valve replace- 
ment 
Previous car 4 4 3 
diac operation 
Mitral annulo- 2 3 3 
plasty 
Other 2 
Duration of opera- 178 _+ 77 188 + 41 184 _+ 55 
tion (min) 
Duration of CPB 87 _+ 25 89 -+ 40 99 _+ 36 
(rain) 
Duration of ischemia 46 _+ 10 46 -+ 19 47 ___ 21 
(rain) 
Age and times are expressed as mean plus or minus tandard eviation. No 
significant differences between groups were observed. CABG, Coronary 
artery bypass grafting. 
antiaggregant drugs or deficient heparin neutraliza- 
tion by protamine. 4-w 
In recent years, efforts have been made to design 
strategies to reduce and control bleeding pharma- 
cologically. Treatments with prostacyclin, la antifi- 
brinolytic drugs (aminocaproic acid, t2 tranexamic 
acid, 13 or aprotinin), or desmopressin 14 have been 
used for this purpose. 
It has been widely demonstrated that aprotinin 
administration reduces blood loss and blood re- 
quirements in patients undergoing CPB. 15-24 Apro- 
tinin is a serine protease inhibitor that efficiently 
inactivates plasmin and kallikrein, 25 thereby inhibit- 
ing fibrinolysis and possibly preserving platelets of 
activated proteases. 22' 23 
In contrast, the efficacy of desmopressin CPB 
varies with the different works reviewed. 14, 26-30 Des- 
mopressin is a synthetic analog of vasopressin. Its 
administration increases levels of factor VI I I  and 
high-molecular-weight multimeric forms of von Wil- 
lebrand's factor. Its utility has been demonstrated in 
moderate hemophilia A, in some variants of von 
Willebrand's disease, and in a heterogeneous group 
of disorders with prolonged bleeding time. 31-33 
To our knowledge, there have been no compara- 
tive studies on the efficacy of aprotinin versus des- 
mopressin in CPB. We therefore performed a dou- 
ble-blind, randomized, prospective study comparing 
aprotinin, desmopressin, and placebo in an attempt 
to demonstrate heir effectiveness in reducing blood 
loss and red blood cell requirements in CPB. We 
also analyzed the influence of each treatment on 
several hematologic and hemostatic parameters. 
Methods 
Patients. To be eligible for recruitment, patients had to 
be older than 18 years and scheduled to undergo either 
coronary artery bypass grafting, heart valve replacement 
or annuloplasty, combined valve replacement and coro- 
nary artery bypass grafting, or closure of atrial septal 
defects. Patients requiring emergency operations and 
those with a history of any bleeding disorder, with a 
history of allergy, or with previous exposure to aprotinin 
were not included. Demographic data are summarized in
Table I. 
Surgical procedures. Anesthetic, surgical, and CPB 
procedures were done according to the institutional pro- 
tocols of the Hospital de Sant Pau (Barcelona, Spain) and 
were similar in all three groups. Patients received chloraz- 
epate (0.5 mg/kg body weight) 2 hours before anesthesia 
was induced. All patients' conditions were monitored by 
recording a continuous electrocardiogram, the central 
venous pressure, the arterial pressure by a radial artery 
catheter, esophageal and rectal temperatures, hourly 
urine output, and sequential blood gas measurements. A 
pulmonary artery catheter was placed in patients with a 
poor cardiac index (<0.5). 
Anesthesia was induced with flunitrazepam (0.02 mg/kg 
body weight) and fentanyl (10 to 20 ttg/kg body weight). 
Pancuronium bromide (0.1 mg/kg body weight) was used 
for muscle relaxation. Anesthesia was maintained with 
successive doses of fentanyl. Isoflurane (0.5% to 1%) was 
added to the ventilation system when needed. 
The CPB device was primed with Ringer's solution, 
polygeline, and mannitol. Extracorporeal circulation was 
instituted at 28 ° C with an output of 2.2 to 2.4 L/m 2 per 
minute. Perfusion pressure was maintained between 50 
and 80 mm Hg. A cardioplegic solution containing man- 
nitol (8.9 gin/L), dextrose (4.5 gm/L), potassium (30 
mmol/L), chloride (113 mmol/L), sodium (82 mmol/L), 
and bicarbonate (20 mmol/L) was injected every 20 min- 
utes into the aortic root. 
Anticoagulation was achieved with heparin (300 IU/kg 
body weight) injected into the right atrium. Successive 
doses of heparin were given during CPB. Because aproti- 
nin can prolong activated clotting time (Hemochron 401 
device, International Technidyne Corp., Edison, N.J.), 23 
patients in whom the first activated clotting time measure- 
ment was greater than 750 seconds received heparin to 
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maintain the activated clotting time between 750 and 950 
seconds, and in those patients in whom the first activated 
clotting time measurement was about 400 seconds, acti- 
vated clotting time was maintained between 400 and 500 
seconds. Activated clotting time assays were not done by 
the participants in the study and the activated clotting 
time results were not revealed. All groups received hepa- 
rin in similar dosages. When surgical procedures were 
finished and CPB was stopped, heparin neutralization 
with protamine sulfate was achieved by means of an 
infusion of 1.5 mg/100 IU of heparin administered. Pa- 
tients were later cared for in the postoperative intensive 
care unit. 
Transfusions were administered according to the fol- 
lowing criteria: red blood cells were given when the 
hemoglobin value was less than 80 gm/L (70 gm/L in CPB 
period) or when the patient was in shock because of 
hemorrhage, fresh frozen plasma was given if microvas- 
cular bleeding was present with a prothrombin interna- 
tional normalized ratio greater than 1.5 or a fibrinogen 
level less than 1 gin/L, and platelet concentrates were 
given in cases of microvascular bleeding and platelet 
counts less than 60,000/tzl. 
Study design. The study protocol was approved by the 
Ethical Clinical Trials Committee. After informed con- 
sent was obtained, each patient was independently ran- 
domized to either the placebo or drug groups. Expected 
duration of CPB was taken into account for randomiza- 
tion. Multiple valve replacements, valve replacement plus 
mitral annuloplasty, bypass grafting of more than two 
arteries, valve replacement plus coronary artery bypass 
grafting, and procedures in patients with a history of 
previous cardiac operation were considered long duration 
procedures (->120 minutes of expected CPB time). 
On the basis of our previous experience, a sample size 
of 50 patients in each group was estimated as having 80% 
power (type II error of 0.2) to demonstrate a statistically 
significant result if the true reduction of blood loss was 
50%, assuming a critical p value of 0.05 (two-sided test). 
We also assumed a reduction in effective sample size of 
20% because of patients eliminated from the study. 
Sealed envelopes ensured that only the pharmacist who 
prepared the encoded infusions knew whether a patient 
received desmopressin, aprotinin, or placebo. All three 
compounds were prepared with the same outward appear- 
ance. Dosage schedules are shown in Table ii. 
Patients randomized to the desmopressin group re- 
ceived desmopressin (Ferring Pharmaceuticals, Malmoe, 
Sweden) as follows: patients with body weight less than 65 
kg were given infusions of 20 t~g and other patients 
received 24 /xg (corresponding to 0.3 to 0.4 /xg/kg body 
weight). At time 4 (see Table II), desmopressin was 
infused in 50 ml of saline solution for 20 to 30 minutes, 15 
minutes after protamine administration. In other phases, 
patients received saline solution only. 
Aprotinin (Trasylol, Bayer AG, Leverkusen, Germany) 
was administered in saline solution without additives or 
preservatives. The following dosage regimen was used in 
this treatment group: before anesthesia n infusion of 
2,000,000 KIU was given over 20 to 30 minutes. A dose of 
2,000,000 KIU was added to the priming solution of the 
heart-lung machine. Aprotinin was administered continu- 
Table H. Dosage schedule 
Volume administered 
Desmopressin 
Placebo group group Aprotinin group 
Time 1 PS 200 ml PS 200 ml Aprotinin 200 ml 
Time 2 PS 200 ml PS 200 ml Aprotinin 200 ml 
Time 3 PS 50 ml/hr PS 50 ml/hr Aprotinin 50 ml/hr 
Time 4 PS 50 ml Desmopressin PS 50 ml 
50 ml 
Time 1, Start of anesthesia; time 2, drug in fluid prime; time 3, skin incision 
to skin closure; time 4, after protamine neutralization; PS, physiologic 
saline solution. 
ously at 500,000 KIU per hour until the end of the 
operation (from skin incision to skin closure). At time 4, 
these patients received saline solution. 
Patients in the placebo group received saline solution 
during all the stages. 
Measurement of blood loss. Intraoperative blood loss 
was estimated by weighing the gauze sponges and mea- 
suring the contents of the reservoir of the suction device. 
The fluid used for rinsing was subtracted from this 
amount. Blood drained from chest tubes was recorded at 
1, 2, 3, 6, 12, and 24 hours after operation. 
The amounts of red blood cell units, fresh frozen 
plasma, and platelet concentrates infused in each patient 
in the first 24 hours were also registered. 
Laboratory measurements. Blood samples were taken 
as follows: (1) immediately before operation, (2) after 
CPB but before the administration of protamine, (3) 15 
minutes after protamine administration, (4) 60 minutes 
after time 4 (see Table II), and (5) 18 to 24 hours after 
operation. Blood mixed with 0.129 mol/L sodium citrate in 
a 10:1 proportion was obtained for analysis of plasma 
factor VIII coagulant activity (FVIIIc), yon Willebrand's 
factor antigen (vWFAg), thrombin-antithrombin (TAT) 
complexes, and split products of cross-linked fibrin (D- 
dimer). For measurements of hemoglobin and platelet 
count, blood was mixed with ethylenediaminetetraacetic 
acid. Hemoglobin level and platelet counts in whole blood 
were determined by routine analysis with a Coulter 
counter (Coulter Electronics, Luton, England). D-dimer 
and vWFAg levels were measured by an enzyme-linked 
immunosorbent assay method (Boehringer-Mannheim, 
Mannheim, Germany). Levels of TAT complexes were 
determined by sandwich enzyme-linked immunosorbent 
assay (Behring, Marburg, Germany). FVIIIc was quanti- 
fied by one-stage clotting assay. 
It was possible to determine all these biologic parame- 
ters in the five samples from 34 patients in the aprotinin 
group, 35 patients in the desmopressin group, and 41 
patients in the placebo group. 
Statistical analysis, Results are expressed as the mean 
and standard eviations and as the 95% confidence inter- 
val (CI). Percentages are expressed with the CI. All 
relevant differences are shown as the CI of these differ- 
ences. Ap  value less than 0.05 was considered significant. 
Age, body surface area, body weight, and durations of 
operation and extracorporeal circulation were compared 
among groups by one-way analysis of variance. Sex, type 
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Table I I I .  Blood loss 
Blood loss (ml/m 2BSA) 
Aprotinin Desmopressin Placebo 
group group group 
0-1 hr 22 ± 22* 60 + 45 66 - 71 
1-2 hr 18 -+ 16" 51 ± 53 65 ± 62 
2-3 hr 15 _+ 10' 40 _ 32 48 _ 50 
3-6 hr 51 -4- 59* 90 ± 72 131 _ 119 
6-24 hr 89 --- 80* 159 ± 126 179 ± 154 
0-24 hr 195 ± 146" 400 ± 192 489 _+ 361 
Bypass t ime 
<120 mint  
0-6 hr 99 ± 58* 250 ± 155 273 +_ 192 
6-24 hr 77 --_ 40* 162 _+ 137 149 ± 72 
0-24 hr 176 ± 73* 412 ± 200 422 --_ 237 
Bypass t ime 
->120 mint  
0-6 hr 205 ± 193:~ 230 ± 152:~ 428 ± 373 
6-24 hr 184 ___ 2475 120 _+ 31:~ 270 ± 287 
0-24 hr 389 ± 4335 350 ± 159:~ 698 --_ 572 
Values given as mean plus or minus standard eviation, 
*p < 0.001 aprotinin versus desmopressin or placebo. 
tp < 0.001 long duration versus hort duration (analysis of variance with 
two factors). 
:~p < 0.05 aprotinin or desmopressin versus placebo. 
of operation, and previous treatment were compared by a 
X a test. Primary efficacy analysis was done on the total 
blood loss during the first 24 hours after operation by an 
analysis of variance with two factors (treatment and CPB 
duration, long versus hort). A sequential sum of squares 
method was used because the numbers of patients in the 
short and long duration groups were very different. An 
analysis of variance for repeated measures with one factor 
(treatment) was done to analyze the blood loss profiles at 
1, 2, 3, 6, and 24 hours, and CPB duration was used as 
covariable. Polynomial contrasts were applied within dif- 
ferent points to analyze different trends of each treatment. 
Bonferroni's correction was applied for multiple compar- 
isons. A multiple regression analysis was done to evaluate 
the relationship between overall blood loss and some 
clinical or biologic variables. 
Differences between percentages of patients receiving 
transfusion were estimated with a X 2 method. In patients 
receiving transfusion, differences in the number of blood 
units were assessed by analysis of variance with CPB 
duration as a covariable. A logistic regression model was 
used to estimate the odds ratio of undergoing transfusion 
in each treatment group. Age, sex, CPB duration, preop- 
erative hemoglobin value, and preoperative platelet count 
were included as adjustment variables. The improvement 
in =2 log likelihood was evaluated to establish the good- 
ness of fit of the model. The evolution of biologic param- 
eters throughout the CPB period was assessed by analysis 
of variance for repeated measures (treatment as the factor 
and CPB duration as the covariable). Polynomial con- 
trasts were applied to evaluate profiles between treat- 
ments. If no influence of the analyzed factors was ob- 
served, a simple analysis of variance for repeated 
measures was used. D-dimer values were analyzed with 
the use of a logarithmic transformation. 
Results 
Clinical setting. The characteristics of the three 
groups are summarized in Table I. A total of 150 
patients were considered for entry, one of whom 
refused inclusion in the study. The aprotinin group 
comprised 48 patients, the desmopressin group 50, 
and the placebo group 51. Age, sex, weight, previous 
anticoagulant or antiaggregant treatment, and type 
of operation were similar in the three groups. In 
patients receiving oral anticoagulation, anticoagu- 
lants were stopped and basic hemostatic test results 
were normal before the operation. Operative and 
CPB durations were longer in the placebo group but 
differences were not significant. 
Safety. No adverse reactions to the drugs used 
were noted. Six patients died during the operation: 
two in the aprotinin group, three in the desmopres- 
sin group, and one in the placebo group. All of these 
were undergoing coronary artery bypass grafting. In 
every case, death was in relation to a previous evere 
ischemic cardiomyopathy and no relationship with 
the treatment regimen was found. Moreover, the 
patients who died in the desmopressin group died 
before drug administration. Three patients required 
reoperation because of bleeding related to the op- 
eration (1 in the aprotinin group and 2 in the 
desmopressin group) and were excluded from data 
analysis. As for thromboembolic complications, one 
patient from the placebo group had a femoral 
embolism on the first day, one patient from the 
desmopressin group with dilated cardiomyopathy 
had an ischemic stroke 6 days after operation, and 
one patient from the aprotinin group had a femoral 
embolism 6 days after operation. 
Blood loss. The results of the study are summa- 
rized in Table III. When blood loss was analyzed 
with regard to type of operation o differences were 
found. However, blood loss was different in relation 
to treatment and CPB duration (p < 0.001). Intra- 
operative bleeding showed no differences between 
groups. When total bleeding was considered (first 24 
hours), patients in the aprotinin group bled less than 
others. They lost 195 _ 146 ml/m 2 body surface area 
(BSA) compared with 400 + 192 ml/m 2 BSA in the 
desmopressin group and 489 _+ 361 ml/m 2 BSA in 
the placebo group (95% CI: difference between 
desmopressin and aprotinin groups 98 to 312 ml/m 2 
BSA, p < 0.001; difference between placebo and 
aprotinin groups 190 to 398 ml/m 2 BSA, p < 0.001). 
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Fig, 1. Red blood cell transfusion requirements by number of units (no. units). Patients in aprotinin group 
received fewer transfusions than others (*p < 0.001). BoM squares denote no transfusion. 
The increment of blood loss throughout the obser- 
vation period was linear in all three groups (polyno- 
mial contrasts; explained variability for linear trend, 
90% in the aprotinin group, 93% in the desmopres- 
sin group, 80% in the placebo group). 
Hemorrhage was significantly more pronounced in 
patients with longer CPB times (see Table III). The 
duration of CPB exceeded 120 minutes in 25 patients 
(4 with aprotinin, 9 with desmopressin, and 12 with 
placebo). In this set of patients, total blood loss was 
389 ± 433 ml/m 2 BSAwith aprotinin, 350 +__ 159 ml/m 2 
BSA with desmopressin, and 698 ± 572 ml/m 2 BSA 
with placebo. Differences between the aprotinin and 
desmopressin groups versus the placebo group were 
significant (95% CI: difference between placebo and 
aprotinin groups 29 to 590 ml/m 2 BSA, p < 0.05; 
difference between placebo and desmopressin groups 
135 to 563 ml/m 2 BSA, p < 0.05). 
Blood products requirement. Red blood cell 
transfusion was required in only 26% (95% CI: 15% 
to 42%) of patients who received aprotinin com- 
pared with 66% (95% CI: 51% to 80%) in the 
desmopressin group and 56% (95% CI: 41% to 
70%) in the placebo group. Differences between 
aprotinin versus placebo plus desmopressin were 
significant (95% CI: 51% to 71%; p < 0.001). No 
differences between the placebo and desmopressin 
groups were observed (see Fig. 1). 
The administration of aprotinin protected 
against he need for red blood cell transfusion as 
compared with administration of placebo, with a 
crude odds ratio of 0.31 (95% CI, 0.13 to 0.71; 
improvement X 2 14.87, p = 0.0006). No effect was 
seen in the desmopressin group (crude odds ratio 
1.46; 95% CI, 0.66 to 3.25). When the model was 
adjusted for age, sex, initial hemoglobin value and 
CPB duration (more than 120 minutes, less than 
120 minutes), patients with long CPB procedures 
had a higher risk of receiving red blood cell units 
(adjusted odds ratio 12.32; 95% CI, 2.95 to 51.21). 
The patients in whom initial hemoglobin levels 
were higher had a lower risk of transfusion (ad- 
justed odds ratio 0.36; 95% CI, 0.17 to 0.75; 
improvement X 2 41.87, p < 0.0001). 
Requirements expressed as mean (range) of red 
blood cell units were 0.7 (0 to 6) units in the 
aprotinin group, 1.6 (0 to 6) in the desmopressin 
group, and 1.8 (0 to 8) in the placebo group. If we 
consider only patients who received transfusion, no 
significant differences among groups were observed 
in relation to the number of red blood cell units 
transfused (2.54 ± 1.81 in the aprotinin group, 
2.59 -+ 1.54 in the desmopressin group, and 3.25 _+ 
1.96 in the placebo group). In long duration proce- 
dures, differences among groups were also not 
found (aprotinin group 2.25 ___ 1.89 units, desmo- 
pressin group 2.28 ___ 1.50 units, and placebo group 
4.36 -+ 2.34 units). Patients with short procedures 
received 46% fewer transfusions (95% CI, 31% to 
62%) than others. 
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Fig. 2. Evolution of hemoglobin levels throughout observation period. All groups howed ecrease caused 
by hemodilution, but at end of CPB (fourth determination), hemoglobin level was higher in patients who 
received aprotinin (*p < 0.05). At 24 hours, there were no differences between groups, but desmopressin 
and placebo groups received more red blood cell units. PT, Protamine. 
Five patients (1 from the placebo group and 4 from 
the desmopressin group) needed fresh frozen plasma 
transfusion, and platelet concentrates were given to 
nine patients (1 from the aprotinin group, 3 from the 
desmopressin group, and 5 from the placebo group). 
Hematologic parameters. All groups had similar 
presurgical levels of hemoglobin. A decrease was 
observed uring CPB mainly because of hemodilu- 
tion and was followed by a slight rise. The hemoglo- 
bin level at the end of CPB was significantly higher 
in patients who received aprotinin. Nevertheless, no 
difference was observed in the hemoglobin measure- 
ment at 24 hours. This could be explained by the fact 
that the aprotinin group received fewer transfusions 
than the other groups (Fig. 2). The platelet count 
decreased in all patients during CPB and no differ- 
ences among groups were observed. FVIIIc and 
vWFAg levels also decreased in the extracorporeal 
period probably in relation to hemodilution (see 
Table IV). Subsequently, vWFAg levels increased 
with respect to the initial values. No differences 
were noted in these two factors in patients treated 
with desmopressin. Measurements of TAT com- 
plexes were not statistically different and a dramatic 
increase was observed in all patients throughout the 
CPB period (see Table IV). 
As for D-dimer, the evolution was clearly differ- 
ent among groups (see Fig. 3 and Table IV). Pa- 
tients receiving desmopressin or placebo showed a 
marked increase in D-dimer levels during CPB 
(explained variability for quadratic trend, 80%). In 
contrast, patients treated with aprotinin showed a 
slight rise in D-dimer levels at the end of CPB 
(explained variability for linear trend, 50%; qua- 
dratic trend, 43%). Differences between the aproti- 
nin group and the desmopressin or placebo groups 
were significant. A regression multiple analysis with 
the following variables was applied: all biologic 
parameters at the end of CPB, CPB duration, type 
of treatment, and overall bleeding as dependent 
variable. A multiple regression coefficient of 0.61 
(F = 17.36,p < 0.0001) was obtained. Only D-dimer 
level and the use of aprotinin were significant. The 
equation of this model was as follows: overall bleed- 
ing = 382.7 + 0.013 (D-dimer) - 242.8 aprotinin, 
where overall bleeding units are milliliters per meter 
squared, D-dimer units micrograms per liter, and 
aprotinin can be 1 (if used) or 0 (if not used). Fig. 4 
represents the linear correlation between overall 
blood loss and the level of D-dimer at the end of 
CPB in the desmopressin and placebo groups, but 
not in the aprotinin group. 
Discussion 
The management of bleeding remains a major 
challenge in patients undergoing CPB procedures. 
Different pharmacologic strategies have recently 
been the focus of attention given that their use is 
potentially less hazardous than the administration of
blood products. Two drugs have demonstrated their 
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Fig. 3. D-dimer levels markedly increased during CPB in desmopressin and placebo groups, but not in 
aprotinin group (*p < 0.05). D-dimer level is expressed as geometric means. PT, Protamine. 
Table IV. Biological parameters in the three treatment groups 
Groups 
Aprotinin (n = 34) Desmopressin (n = 35) Placebo (n = 41) 
D-dimer (/zg/L) 
Before operation 
Before protamine 
After protamine (15 min) 
After protamine (75 min) 
18-24 hr 
TAT complexes (/xg/L) 
Before operation 
Before protamine 
After protamine (15 min) 
After protamine (75 min) 
18-24 hr 
FV[IIc (%) 
Before operation 
Before protamine 
After protamine (15 rain) 
After protamine (75 min) 
18-24 hr 
vWFAg (%) 
Before operation 
Before protamine 
After protamine (15 min) 
After protamine (75 min) 
18-24 hr 
1852 ± 876 1545 ± 469 2526 ± 1128 
1646 ± 795 3172 ± 909* 6014 ± 2291" 
1957 ± 985 3834 ± 963* 7601 ± 2557* 
4205 ± 2344 3877 ± 1296" 6809 ± 2365* 
4714 ± 2999 4064 ± 1087 4927 ± 2156 
13.3 ± 13.9 19.2 --- 23.1 22.9 ± 26.1 
55.9 ± 43.9 95.3 ± 77.3 76.7 ± 49.8 
85.9 ± 51.5 122.4 --- 120.7 92.9 ± 48.3 
56.7 -+ 48.8 68.2 ± 61.8 59.1 ± 28.8 
24.2 ± 28.2 29.0 ± 44.9 18.6 ± 11.5 
117 ± 68 115 ± 46 121 ± 55 
17± 17 22±35 12± 11 
76 ± 33 72 +_ 37 68 ± 30 
106 ± 46 101 ± 42 92 ± 48 
124 ± 52 119 ± 40 133 ± 42 
145 + 73 154 -+ 77 151 + 67 
126 ± 71 126 _+ 65 142 -+ 73 
152 ± 70 148 +_ 76 164 +- 69 
184 ± 84 181 -+ 70 177 ± 79 
206 ± 98 185 ± 77 198 -+ 78 
Values given as mean plus or minus standard eviation except for D-dimer values, which are given as mean plus or minus standard error. 
TAT, vWFAg, and FVnIc values howed no differences among roups. D-dimer level was higher in the placebo and desmopressin groups. 
*p < 0.05. 
possible usefulness: aprotinin and desmopressin. 
The efficacy of desmopressin s still controversial. 
Salzman j4 and Czer 26 and their colleagues found a 
beneficial effect in patients with a long duration of 
CPB and severe bleeding. By contrast, other authors 
demonstrated no reduction in bleeding, as' 29 The 
different conclusions could possibly be explained by 
the fact that the populations were not comparable. 
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Fig. 4. Correlation between overall blood loss (in millili- 
ters per meter squared) and D-dimer measurement af er 
protamine neutralization i desmopressin a d placebo 
groups (p < 0.01). This correlation did not exist in 
aprotinin groups, logDD, Logarithm of D-dimer. 
On the other hand, in our own clinical experience 
some patients howed a good response to desmo- 
pressin infusion. For these reasons we decided to 
include in our study a treatment group receiving 
desmopressin. Moreover, aprotinin has proved to be 
beneficial in reducing blood loss in operations done 
with CPB, 15-24 but to ourknowledge no comparative 
study of aprotinin and desmopressin has been done. 
Bleeding. The overall analysis of blood loss re- 
vealed a beneficial effect of aprotinin in operations 
done with CPB. Its use reduced bleeding roughly by 
half compared with results with desmopressin or 
placebo. No overall differences were noted befween 
the placebo and desmopressin groups. As for CPB 
duration, patients with long CPB times (longer than 
120 minutes) had more bleeding. Eighteen patients 
initially randomized as requiring a long duration of 
CPB (10 in aprotinin group, 5 in desmopressin 
group, and 3 in placebo group) had shorter CPB 
times. There were fewer patients with a long dura- 
tion of CPB in the aprotinin group than in the other 
groups. A possible advantage of aprotinin in this 
reduction could not be demonstrated. Although the 
group of patients with CPB times exceeding 120 
minutes was small, aprotinin and desmopressin 
seemed to be more effective than placebo in pre- 
venting bleeding. One recent report found no ad- 
vantage with desmopressin in operations done with 
CPB, 3° but desmopressin was administered only if 
significant postoperative bleeding was present and 
the authors did not distinguish between short and 
long CPB durations. A recent report supports des- 
mopressin as being safe and useful in reducing blood 
loss and transfusion requirements in patients with 
excessive bleeding after operations with CPB. 34 We 
found no differences between groups with respect to 
previous intake of antiaggregant or anticoagulant 
drugs and no influence was confirmed in bleeding 
complications. 
Blood product requirements. Reduction of blood 
loss in patients treated with aprotinin was followed 
by a saving in blood products. Only a quarter of 
these patients needed red blood cell units. In con- 
trast, more than half the patients in other groups 
received transfusions. Although the level of hemo- 
globin at the end of CPB was slightly higher in the 
aprotinin group, it was similar in all groups at 24 
hours after the operation. This finding can be easily 
explained by a higher rate of transfusion eeds in 
the desmopressin and placebo groups. When CPB 
duration was longer than 120 minutes, nearly all the 
patients required transfusion. Patients treated with 
aprotinin or desmopressin received a smaller num- 
ber of red blood cell units than patients in the 
placebo group, but the differences were not signifi- 
cant. No comparisons could be made with respect to 
other types of blood products because their use was 
minimal. Nevertheless, except for one patient in the 
aprotinin group, all platelet or plasma transfusions 
were given to patients treated with desmopressin or 
placebo. 
Safety. No hypersensitive or other adverse reac- 
tions related to the administration f desmopressin 
or aprotinin were observed. Six patients died during 
the operation (2 in the aprotinin group, 3 in the 
desmopressin group, and 1 in the placebo group). 
All were patients requiring coronary artery bypass 
grafting. Death was due to surgical or hemodynamic 
complications related to a previous evere ischemic 
cardiomyopathy, and no relationship with the treat- 
ment regimen was found. It should be pointed out 
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that the three patients who died in the desmopressin 
group died before the drug was administered. In
coronary artery bypass grafting we did not perform 
an angiographic evaluation of bypass patency after 
the operation, although no differences between 
groups were observed for frequencies of myocardial 
infarction or unstable angina. Moreover, the clinical 
assessment of patients' conditions 1 year after the 
operation disclosed no differences with respect o 
the prevalence of recurrent angina or myocardial 
infarction among groups. Three late thromboem- 
bolic events were observed, one in each group. 
Relationship with the drug used was unlikely. A 
recent analysis of studies that compared hemostatic 
efficacy of desmopressin versus placebo concluded 
that desmopressin does not increase the prevalence 
of thrombosis. 35 
Hematologic measurements. It is widely known 
that desmopressin produces an increase in plasma 
levels of FVIIIc and vWFAg, 32 which proceed from 
endothelial cells. In common with other authors 28 
we did not find any differences between groups in 
relation to FVIIIc and vWFAg levels. All groups 
showed a similar increase in both factors after CPB. 
The known effect of aprotinin in hemostasis i
caused by its ability to inhibit plasmin and kallikrein. 
Kallikrein plays a role in the activation of the 
intrinsic pathway of blood coagulation. Recently, 
this pathway of clotting activation has been consid- 
ered to be of less importance. 36 Kallikrein also 
participates in the intrinsic fibrinolytic activation 
pathway. However, the advantage ofaprotinin prob- 
ably springs from its capacity to inhibit plasmin. 25 In 
operations with CPB there is a marked activation of 
coagulation caused by tissue injury, platelet destruc- 
tion, and contact with foreign surfaces. Coagulation 
activation can be estimated by levels of TAT com- 
plex, a thrombin generation marker. 37 No differ- 
ences in TAT complex levels were found between 
groups. This could indicate that clotting activation 
was similar in the three groups. D-dimer is a fibrino- 
lytic marker because it is formed by the action of 
plasmin over cross-linked fibrin. In our study, the 
patients who received aprotinin showed no signifi- 
cant increase in D-dimer levels, whereas patients 
who received esmopressin a d placebo underwent 
a dramatic rise in D-dimer levels. Patients receiving 
aprotinin thus had an efficient inhibition of fibrinol- 
ysis. CPB-associated hyperfibrinolysis has been pos- 
itively correlated with bleeding. 38 We found a cor- 
relation between overall blood loss and D-dimer 
level in patients treated with desmopressin or pla- 
cebo, but not in those in the aprotinin group. In the 
aprotinin group, there was a poor fibrinolytic re- 
sponse caused by plasmin inhibition. Moreover, the 
multiple regression model shows that the use of 
aprotinin is clearly related to a reduction of blood 
loss. 
Conclusion. We can conclude that the adminis- 
tration of aprotinin to patients undergoing opera- 
tion with CPB significantly reduces blood loss and 
blood cell requirements. Aprotinin produces a 
marked inhibition of fibrinolysis in vivo, which may 
be important in explaining its positive effect on 
reducing blood loss. 
Although the administration f desmopressin did 
not show any benefit in overall bleeding, it may be 
useful for patients who have long duration proce- 
dures, because it is administered after the end of 
CPB. We would like to emphasize that in our 
experience aprotinin treatment is safe and should be 
used in all patients undergoing CPB provided they 
have no history of aprotinin allergy. Given that the 
mechanisms of action of desmopressin a d aproti- 
nin are different, further studies are necessary totest 
the possible synergic benefits of aprotinin together 
with desmopressin in operations done with CPB. 
We are indebted to Dr. J. Ma. Badenas (Research and 
Development Department, Q. F. Bayer) and Dr. L. 
Ribera, Jr. (Hospital Sant Pau), for their technical ssis- 
tance and to Mrs. Caroline Newey and Mr. Georges von 
Knorring for review of the manuscript. 
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